Surveying respiratory infections among Iranian Hajj pilgrims

authors:

avatar Seyed Mansour Razavi 1 , * , avatar Hossein Ziaee 1 , avatar Talaat Mokhtari Azad 1 , avatar Rasoul Hamkar 1 , avatar Taher Doroodi 1 , avatar Aliakbar Mirsalehian 1 , avatar Farrokh Nakhjavan 1 , avatar Farhad Nejat 1 , avatar Hamidreza Sadeghipoor 1 , avatar Ahmad Masoud 1 , avatar Parivash Kordbacheh 1 , avatar Farideh Zeini 1 , avatar Mahin Saf Ara 1 , avatar Mohammad Mir Afshar 1 , avatar Kobra Bamdad Mehraban 1 , avatar Farzaneh Bazarjani 1

Department of Social Medicine, Tehran University of Medical Sciences, Tehran, Iran

how to cite: Razavi S M, Ziaee H, Mokhtari Azad T, Hamkar R, Doroodi T, et al. Surveying respiratory infections among Iranian Hajj pilgrims. Arch Clin Infect Dis. 2007;2(2): 67-70. 

Abstract

Background:

The annual Hajj pilgrimage to Mecca brings over two million people together in a small confined area. Respiratory involvement is the most common disease during this ceremony, and up to now no unique cause has been identified. The present study was conducted to determine the incidence and types of respiratory diseases and their associated etiologic agents.

Materials and methods:

During this prospective study, seroconversion was assessed for bacteria, viruses and fungi on 170 Iranian pilgrims prior to departure and 2 weeks after convalescence and returning from the Hajj pilgrimage. Meanwhile, sputum specimens of 252 patients were cultured.

Results:

The following viruses were detected: influenza type A and B (21.5%), adenovirus (36.2%), and RSV (1.9%). Among bacteria isolates, ?-haemolytic Streptococcous (9.7%), Haemophilus species (9.1%), Gram negative bacilli (20.6%), Legionella pneumophila (6.3%), Mycoplasma pneumonia (0.8%), and Chlamydia (32%) were more common, however, no fungal seroconversion was noted.

Conclusion:

We suggest administration of Fluvaccin for high risk groups, adenoviral vaccine for volunteer pilgrims, erythromycin or azithromycine for empiric bacterial therapy, and Oseltamivir or Zanamivir for prophylaxis or treatment of influenza like illness.

Full Text

Full text is available in PDF